CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) will present Tuesday, Aug. 11, at the Canaccord Genuity 46th Annual Growth Conference, giving investors an opportunity to hear from the company as it advances the commercial and clinical strategy for its MASH treatment franchise.
The presentation is scheduled for 12 p.m. EDT and will be webcast live, Madrigal reported. A replay will be available following the event.
Madrigal is focused on treatments for metabolic dysfunction-associated steatohepatitis, or MASH, a liver disease that can progress to cirrhosis and other serious complications.
Its lead commercial product, Rezdiffra, or resmetirom, is a once-daily oral THR-β agonist. The drug became the first treatment approved by both the U.S. Food and Drug Administration and European Commission for MASH with moderate to advanced fibrosis, classified as stages F2 to F3.
The company is also seeking to extend Rezdiffra’s reach into more advanced disease. An ongoing Phase 3 outcomes trial is evaluating the treatment in patients with compensated MASH cirrhosis, or F4c.
Madrigal did not specify what executives plan to discuss at the Canaccord conference or identify the company representatives who will participate.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.